Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $35,422.53 in Stock

by · The Cerbat Gem

Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Free Report) CEO Daniel Barber sold 8,257 shares of the stock in a transaction on Friday, May 15th. The stock was sold at an average price of $4.29, for a total value of $35,422.53. Following the completion of the sale, the chief executive officer directly owned 660,574 shares in the company, valued at $2,833,862.46. This represents a 1.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Barber also recently made the following trade(s):

  • On Tuesday, March 10th, Daniel Barber sold 180,677 shares of Aquestive Therapeutics stock. The shares were sold at an average price of $4.17, for a total transaction of $753,423.09.

Aquestive Therapeutics Stock Performance

Aquestive Therapeutics stock opened at $4.17 on Thursday. Aquestive Therapeutics, Inc. has a one year low of $2.22 and a one year high of $7.55. The company has a 50-day simple moving average of $4.15 and a 200-day simple moving average of $4.71. The firm has a market capitalization of $523.13 million, a P/E ratio of -6.84 and a beta of 1.50.

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.07. The firm had revenue of $14.45 million during the quarter, compared to the consensus estimate of $10.90 million. As a group, sell-side analysts forecast that Aquestive Therapeutics, Inc. will post -0.43 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. NewEdge Advisors LLC bought a new stake in Aquestive Therapeutics during the third quarter worth approximately $28,000. BNP Paribas Financial Markets raised its stake in shares of Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after buying an additional 4,134 shares in the last quarter. Modern Wealth Management LLC acquired a new stake in shares of Aquestive Therapeutics in the second quarter valued at $33,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of Aquestive Therapeutics in the first quarter valued at $42,000. Finally, ADAR1 Capital Management LLC boosted its stake in Aquestive Therapeutics by 103.9% during the first quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock valued at $42,000 after buying an additional 264,000 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Monday, April 20th. Lake Street Capital set a $6.00 target price on Aquestive Therapeutics in a research note on Tuesday, February 3rd. Oppenheimer began coverage on Aquestive Therapeutics in a research report on Friday, April 24th. They set an “outperform” rating and a $8.00 price target for the company. Finally, Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $8.80.

Read Our Latest Stock Report on AQST

Aquestive Therapeutics Company Profile

(Get Free Report)

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.

See Also